Mirvetuximab soravtansine (MIRV) is an antibody drug conjugate comprised of a folate receptor alpha-targeted monoclonal antibody and the anti-tubulin maytansinoid payload, DM4. Here the authors report the results of a phase II trial of MIRV in combination with anti-PD1 pembrolizumab in patients with recurrent folate receptor alpha-positive uterine serous carcinoma.
- Rebecca L. Porter
- Yinglu Zhou
- Panagiotis A. Konstantinopoulos
